Markers of the p53 pathway further refine molecular profiling in high-risk endometrial cancer: A TransPORTEC initiative.
RJ Edmondson, EJ Crosbie, M Nickkho-Amiry, A Kaufmann, E Stelloo, HW Nijman, A Leary, A Auguste, L Mileshkin, P Pollock, HJ MacKay, ME Powell, T Bosse, CL Creutzberg, HC Kitchener
Gynecol Oncol | Published : 2017
BACKGROUND: The morphological classification of high-risk endometrial cancer is of limited prognostic value. Recent attempts to stratify tumours according to molecular signatures have shown considerable promise. Here we attempted to further refine molecular classifications using markers of the p53 pathway. METHODS: We analysed the expression of p53 as well as three downstream markers of the p53 pathway, p21, mdm2 and phospho-p63 (pp63), by immunohistochemistry in a series of 114 endometrial cancers (86 endometrioid, 28 non-endometrioid subtype) with high-risk features (such as high tumour grade and deep myometrial invasion) and correlated results with clinical outcome. The Cancer Genome Atla..View full abstract
Awarded by Department of Health